| Literature DB >> 35678389 |
Sebastián Sanz-Martos1, María Dolores López-Franco1, Cristina Álvarez-García1, Nani Granero-Moya1,2, José María López-Hens3, Sixto Cámara-Anguita3, Pedro Luis Pancorbo-Hidalgo1, Inés María Comino-Sanz1.
Abstract
INTRODUCTION: In recent years, the use of drones in health emergencies has increased. Among their main benefits are avoiding endangering rescuers, travelling long distances in a short time, or contacting victims in risky situations; but despite their multiple advantages, their use has not been fully demonstrated. STUDYEntities:
Keywords: drone; emergency medicine; triage; unmanned aerial vehicle
Mesh:
Year: 2022 PMID: 35678389 PMCID: PMC9280065 DOI: 10.1017/S1049023X22000887
Source DB: PubMed Journal: Prehosp Disaster Med ISSN: 1049-023X Impact factor: 2.866
Databases and Search Strings Used in the Review
| Databases | Search Strings |
|---|---|
| Cuiden Plus | Dron AND emergen |
| Global Health | (UAV or unmanned aerial vehicle or drones) AND (Emergency Medicine or emergency) |
| Lilacs | Dron$ and emergen$ |
| IME | Dron y (emergencia o emergencias) |
| PubMed | (UAV[tiab] or unmanned aerial vehicle[tiab] or drones[tiab]) AND (Emergency Medicine[tiab] or emergency[tiab]) |
| CINAHL | (AB UAV or AB unmanned aerial vehicle or AB drones) AND (AB Emergency Medicine or AB emergency) |
| Scopus | UAV OR unmanned AND aerial AND vehicle OR drones AND emergency AND triage |
| Web of Science | TI=(UAV or unmanned aerial vehicle or drones) AND TI=(Emergency Medicine or emergency) |
| Health and Medical Complete | ti((UAV or unmanned aerial vehicle or drones)) AND ti((Emergency Medicine or emergency)) |
| Science Direct | (UAV or unmanned aerial vehicle or drones) AND (Emergency Medicine or emergency) |
| Dialnet Plus | Dron y (emergencia o emergencias) |
Assessment of Study Quality Using the CASPe Guideline
| Item | Study | |
|---|---|---|
| Jain, et al
| Pardo-Ríos, et al
| |
| 1 | Yes | Yes |
| 2 | Yes | Yes |
| 3 | Yes | Yes |
| 4 | No | No |
| 5 | No | Yes |
| 6 | Yes | Yes |
| 7 | Yes | No |
| 8 | No | No |
| 9 | Yes | Yes |
| 10 | Yes | Yes |
| 11 | Yes | Yes |
Note: Item 1-Is the trial oriented to a clearly defined question; Item 2-Was the allocation of patients to treatments randomized; Item 3-Were all patients who entered the study adequately considered until the end of the study; Item 4-Was the blinding of patients, clinicians, and study personnel maintained; Item 5-Were the groups similar at the start of the trial; Item 6-Were the groups treated similarly at the start of the trial; Item 7-How large was the treatment effect; Item 8-What is the precision of this effect; Item 9-Can these results be applied in local setting or population; Item 10-Were all clinically important outcomes taken into account; Item 11-Do the benefits to be gained justify the risks and costs?
Abbreviation: CASPe, Critical Appraisal Skills Program Spanish.
Assessment of Study Quality Using the TREND Guideline
| Item | Study | |||
|---|---|---|---|---|
| Claesson, et al
| Karaka, et al
| Ochieng, et al
| Haidari, et al
| |
| 1 | Yes | Yes | Yes | Yes |
| 2 | No | No | Yes | No |
| 3 | Yes | Yes | Yes | Yes |
| 4 | Yes | Yes | Yes | Yes |
| 5 | Yes | Yes | Yes | Yes |
| 6 | Yes | Yes | No | Yes |
| 7 | No | No | No | No |
| 8 | NA | NA | NA | NA |
| 9 | No | No | No | No |
| 10 | No | No | Yes | Yes |
| 11 | Yes | Yes | No | Yes |
| 12 | Yes | Yes | NA | No |
| 13 | No | No | NA | NA |
| 14 | No | No | NA | NA |
| 15 | No | No | NA | NA |
| 16 | Yes | Yes | Yes | Yes |
| 17 | Yes | Yes | Yes | Yes |
| 18 | No | No | No | No |
| 19 | No | No | Yes | No |
| 20 | Yes | Yes | Yes | Yes |
| 21 | Yes | Yes | No | No |
| 22 | No | Yes | Yes | Yes |
Note: Item 1-Title and abstract; Item 2-Background; Item 3-Participants; Item 4-Interventions; Item 5-Objectives; Item 6-Variables; Item 7-Sample size; Item 8-Allocation method; Item 9-Blinding; Item 10-Unit of analysis; Item 11-Statistical methods employed; Item 12-Participant flow; Item 13-Recruitment; Item 14-Baseline data; Item 15-Baseline data equivalence; Item 16-Quantitative analysis; Item 17-Results and trends; Item 18-Secondary analysis; Item 19-Adverse effects found; Item 20-Interpretation; Item 21-Extrapolation; Item 22-Evidence as a whole.
Abbreviation: TREND, Transparent Reporting of Evaluations with Nonrandomized Designs.
Figure 1.Flow Chart of the Selection Studies Adapted from the PRISMA Model.
Characteristics of Selected Studies
| Study | Type of Study | Principal Results |
|---|---|---|
|
| Randomized Controlled Trial | In day and night conditions, the time to triage was significantly longer for the group using the drones (8.86 vs 5.24; P = .002 and 11.03 vs 7.54 min; P = .002). No significant differences were found in triage outcome or in the order of priority set (P >.05). |
|
| Quasi-Experimental Study | A total of 20 searches were conducted in each group. The intervention group covered significantly more surface area than the control group (4590 vs 2600m
|
|
| Quasi-Experimental Study | A total of 20 searches were performed. The intervention group covered significantly more surface area (228613 vs 88322m
|
|
| Randomized Controlled Trial | The mean distance travelled was significantly lower for the drone group (920 vs 1091.11; P <.0031) and the percentage of victims found was significantly higher for the drone group (92 vs 66.7% of victims; P <.0001). No statistically significant differences were found for the quality of triage (94 for control group vs 88.4% for intervention group; P <.4719), for the performance of airway opening maneuver (62.5 for control group vs 79.2% for intervention group; P <.3408), nor for the performance of hemorrhagic compression (41.66 for control group vs 8.3% for intervention group; P <.1573). |
|
| Quasi-Experimental Study | The average cost per sample for motorbikes was $24.06 while for drones it was $27.42. At distances of less than 30km, motorbikes dominate delivery times and costs; however, drones become more cost-effective when extended the distance to over 75km. |
|
| Quasi-Experimental Study | For distances <75km, there is an improvement in availability (100 vs 97%) and a reduction in dose cost (0.22 vs $0.31 per dose). The cost reduction is more (0.17 vs $0.31 per dose) for greater distances. |